Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | PGR | P06401 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.52 |
| ▸ | F2R | P25116 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8278749 | 0.85 | F2R (0.65) | MEN1KMT2AHPGDSMN1; SMN2MAPT | |
| SCHEMBL23413181 | 0.79 | RAB9A (0.62) | MEN1KMT2AHPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL10894945 | 0.78 | FNTA (0.62) | MEN1KMT2AHPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL7486448 | 0.78 | CA1 (0.71) | MEN1KMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL7486440 | 0.78 | ALDH1A1 (0.63) | HPGDMAPTALDH1A1MAPK1F2R | |
| SCHEMBL13753201 | 0.77 | EPHX2 (0.72) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL23412364 | 0.77 | RAB9A (0.52) | MEN1KMT2AHPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL9373685 | 0.75 | KMT2A (0.62) | MEN1KMT2AHPGDSMN1; SMN2MAPT | |
| SCHEMBL23412950 | 0.75 | RAB9A (0.66) | MEN1KMT2AHPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL10975643 | 0.75 | F2R (0.73) | HPGDMAPTALDH1A1F2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230058312-A1 | ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE | GAIN THERAPEUTICS SA (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20230058312-A1 | ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE | GAIN THERAPEUTICS SA (CH) | 2023-02-23 | — | — | US | disclosed |
| CN-115397806-A | Aryl and heteroaryl compounds and their therapeutic use in conditions associated with altered activity of galactocerebrosidase | 增益治疗股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| EP-4065546-A1 | ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE | Gain Therapeutics SA (CH) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021105906-A1 | ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE | GAIN THERAPEUTICS SA (CH) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021105906-A1 | ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE | GAIN THERAPEUTICS SA (CH) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230058312-A1 | ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE | GBA1, GALC, MAN2B1 | MEN1 4325/4885KMT2A 1760/4885HPGD 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.